At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
PF-06669571 +1 moredrug
Likely dose
PF-06669571 1 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.
In Brief
A Phase 1 clinical trial evaluating PF-06669571 and Placebo for Idiopathic Parkinson's Disease. Completed, enrolled 20 participants across 9 sites.
Detailed Summary
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study will assess whether PF-06669571 is able to demonstrate superior efficacy compared with placebo in the treatment of the motor symptoms of idiopathic Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Parkinson's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionMay 2016
TodayJul 2026
First PostedOct 1, 2015
Enrollment StartNov 16, 2015
Primary CompletionMay 13, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.8 years ago
Interventions
PF-06669571drug
1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
Placebodrug
Placebo